Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765565 | 0.91 | P2RX7 (0.48) | HDAC6POLBSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL3785819 | 0.85 | P2RX7 (0.44) | HDAC6POLBSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL3755932 | 0.84 | ALDH1A1 (0.56) | HDAC6HTTALDH1A1LMNAGAA | |
| SCHEMBL3755499 | 0.83 | P2RX7 (0.41) | HDAC6POLBSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL3759996 | 0.81 | HTT (0.44) | SMN1; SMN2HTTALDH1A1LMNAGAA | |
| SCHEMBL3752434 | 0.80 | HTT (0.43) | SMN1; SMN2HTTALDH1A1LMNAGAA | |
| SCHEMBL3759965 | 0.79 | P2RX7 (0.45) | SMN1; SMN2ALDH1A1LMNAGAAP2RX7 | |
| SCHEMBL3703520 | 0.79 | HTT (0.44) | SMN1; SMN2HTTALDH1A1LMNAGAA | |
| SCHEMBL6369417 | 0.79 | HTT (0.52) | SMN1; SMN2HTTALDH1A1LMNAGAA | |
| SCHEMBL3759959 | 0.79 | P2RX7 (0.41) | SMN1; SMN2LMNAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | claimed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | HDAC6 1249/4885POLB 4177/4885SMN1; SMN2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.